IRIS PubliCatt

De Luca, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.032
EU - Europa 6.596
AS - Asia 2.169
AF - Africa 29
SA - Sud America 13
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 4
Totale 15.852
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.972
DE - Germania 1.776
CN - Cina 1.194
SE - Svezia 1.078
UA - Ucraina 888
PL - Polonia 665
FR - Francia 623
IT - Italia 503
IE - Irlanda 381
SG - Singapore 367
ID - Indonesia 238
FI - Finlandia 217
GB - Regno Unito 198
IN - India 169
RU - Federazione Russa 144
TR - Turchia 81
CA - Canada 36
HK - Hong Kong 31
BE - Belgio 30
NL - Olanda 29
JP - Giappone 25
IR - Iran 23
MX - Messico 12
BZ - Belize 11
KR - Corea 9
CM - Camerun 8
ES - Italia 8
BR - Brasile 7
EU - Europa 7
AE - Emirati Arabi Uniti 6
BG - Bulgaria 6
CH - Svizzera 6
CI - Costa d'Avorio 6
PH - Filippine 6
RO - Romania 6
VN - Vietnam 6
DK - Danimarca 5
GR - Grecia 5
AT - Austria 4
EE - Estonia 4
AU - Australia 3
CL - Cile 3
EG - Egitto 3
LU - Lussemburgo 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GE - Georgia 2
HU - Ungheria 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
MA - Marocco 2
UG - Uganda 2
ZA - Sudafrica 2
AD - Andorra 1
AM - Armenia 1
BN - Brunei Darussalam 1
CO - Colombia 1
EC - Ecuador 1
HR - Croazia 1
IL - Israele 1
IM - Isola di Man 1
IS - Islanda 1
LK - Sri Lanka 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MT - Malta 1
MY - Malesia 1
NG - Nigeria 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PE - Perù 1
PK - Pakistan 1
PT - Portogallo 1
RS - Serbia 1
TN - Tunisia 1
Totale 15.852
Salva come PNG Salva come JPEG
Città #
Chandler 1.369
Jacksonville 569
Kraków 520
Ashburn 463
San Mateo 406
Dublin 378
New York 300
Dearborn 287
Nanjing 275
Jakarta 238
Singapore 238
Wilmington 229
Ann Arbor 171
Houston 168
Lawrence 161
Beijing 158
Cattolica 151
Redmond 143
Warsaw 143
Boston 139
Hangzhou 136
Woodbridge 132
Nürnberg 106
Moscow 104
Nanchang 102
Seattle 99
Redwood City 91
Milan 87
Izmir 78
Princeton 75
Lancaster 73
Boardman 69
Mountain View 67
University Park 64
Shenyang 58
Fairfield 54
Kunming 48
Bremen 43
Hebei 43
Norwalk 43
Changsha 40
Guangzhou 36
Munich 35
Rome 35
Fremont 34
Marseille 34
Jiaxing 33
Brussels 29
Falls Church 28
Philadelphia 28
Tianjin 28
Jinan 27
San Jose 27
Pune 26
Cambridge 25
Hong Kong 25
Verona 24
Los Angeles 22
Leawood 21
Zhengzhou 21
Hefei 20
Shanghai 20
Chicago 19
Ottawa 19
Scottsdale 19
Simi Valley 19
Washington 17
Indiana 14
Augusta 13
Amsterdam 12
Detroit 12
Edinburgh 12
Fuzhou 12
Helsinki 12
Belize City 11
Las Vegas 11
Buffalo 9
Andover 8
Changchun 8
San Francisco 8
Toronto 8
Wenzhou 8
Albuquerque 7
Auburn Hills 7
Lanzhou 7
London 7
Paris 7
Phoenixville 7
Urbino 7
Abidjan 6
Kish 6
Saarbrücken 6
Sofia 6
Tappahannock 6
Tokyo 6
Bari 5
Busto Arsizio 5
Dubai 5
Hanoi 5
Berlin 4
Totale 9.056
Salva come PNG Salva come JPEG
Nome #
Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR 319
Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. 255
Common genetic variation and the control of HIV-1 in humans. 208
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 207
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 195
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 173
Antiretroviral neuropenetration scores better correlate with cognitive performance of HIV-infected patients after accounting for drug susceptibility 173
Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre 158
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 147
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 139
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 137
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 137
Switch to raltegravir-based regimens and HIV DNA decrease in patients with suppressed HIV RNA 134
Relationship between antiretroviral plasma concentration and emergence of HIV-1 resistance mutations at treatment failure 126
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 121
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 121
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. 118
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 117
Highly active antiretroviral therapy and allogeneic CD34(+) peripheral blood progenitor cells transplantation in an HIV/HCV coinfected patient with acute myeloid leukemia 114
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 111
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 110
Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction 108
Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy 108
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 107
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 105
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 105
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 105
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 104
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 104
Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study 103
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy 101
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure. 99
Modulatory effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory activation elicited by gp120 99
Reduced risk of Efavirenz Discontinuation in Naïve Patients Starting First-Line Antiretroviral Therapy with Single Tablet versus dual Tablet Regimen 98
Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome--associated progressive multifocal leukoencephalopathy. 96
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 96
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study 96
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 95
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 95
Cidofovir in addition to antiretroviral treatment is not effective for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis 95
Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop 95
Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: two years experience in routine clinical practice 95
Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients 94
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine versus the 23-valent polysaccharide vaccine in unvaccinated HIV-infected adults: A pilot, prospective controlled study 93
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 93
Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients 92
Serological response to hepatitis B virus vaccine in HIV-infected children in Tanzania 91
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 91
Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure 90
Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study 90
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 89
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 89
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 87
Mitochondrial DNA haplogroups and incidence of lipodystrophy in HIV-infected patients on long-term antiretroviral therapy 87
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 85
Phemphigus vulgaris in a human-immunodeficiency-virus-infected patient. 85
HIV-1 non-R5 tropism correlates with a larger size of the cellular viral reservoir and a detectable residual viremia in patients under suppressive ART 85
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 84
Hyperbilirubinemia during atazanavir treatment in 2404 patients in the Italian atazanavir expanded access program and MASTER Cohorts 84
Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons 84
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial 84
Declining tuberculosis and drug resistance rate among HIV-positive patients at an Italian teaching hospital in the era of highly active antiretroviral therapy 82
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 82
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 82
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). 81
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients 81
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 81
Fatal inflammatory AIDS-associated PML with high CD4 counts on HAART: a new clinical entity? 81
Total cellular HIV-1 DNA decreases after switching to raltegravir-based regimens in patients with suppressed HIV-1 RNA 81
Evolution of antiretroviral prescription and response over a period of 8 years: an Italian multicentre observational prospective cohort study 80
Evolution and predictors of HIV type 1 drug resistance in patients failing combination antiretroviral therapy in Italy 79
Declining Prevalence of HIV-1 Drug Resistance in Antiretroviral Treatment-exposed Individuals in Western Europe 79
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL 79
Lipid-lowering effect of tenofovir in HIV-infected patients 78
Long term follow-up of Nevirapine-treated patients in a single centre cohort 77
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 77
An outbreak of HIV-1 subtype G among Italian injecting drug users 77
Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1 77
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 77
Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine 76
The threshold bootstrap clustering: a new approach to find families or transmission clusters within molecular quasispecies 75
Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. 75
Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals 75
Response to first-line ritonavir-boosted protease inhibitors (PI/r)-based regimens in HIV positive patients presenting to care with low CD4 counts: Data from the Icona Foundation Cohort 74
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 74
Stochastic Modelling of Genotypic Drug-Resistance for Human Immunodeficiency Virus towards Long-Term Combination Therapy Optimisation 73
Interpretation systems for genotypic drug resistance of HIV-1 73
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 73
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 73
Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study 72
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases 71
Italian consensus statement on management of HIV-infected individualswith advanced disease naive to antiretroviral therapy 71
Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients 71
Impairment of recent thymic emigrants in HCV infection. 70
Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time. 70
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 70
Insulin resistance and HCV virologic response to peg-interferons (Peg-IFN) with ribavirin (RBV) in HIV/HCV co-infected patients 69
Routine use of PCR-reverse cross-blot hybridization assay for rapid identification of Mycobacterium species growing in liquid media 69
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 68
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 68
Totale 10.047
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.168
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.168
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.472 0 0 0 87 183 291 152 94 116 132 188 229
2020/20211.750 134 207 45 199 215 99 191 31 272 38 280 39
2021/20221.870 185 198 43 94 68 81 31 315 70 137 260 388
2022/20233.527 475 477 286 502 307 453 82 297 448 36 106 58
2023/20241.724 73 554 31 136 51 379 79 34 18 28 190 151
2024/2025501 83 101 269 48 0 0 0 0 0 0 0 0
Totale 16.041